诱杀癌细胞：PARP 抑制剂及其作用机制。
Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action.
机构信息
Laboratory of Molecular Pharmacology and Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
DNA Damage Response Biology, Oncology IMED, AstraZeneca, Hodgkin Building, B900 Chesterford Research Park, Little Chesterford, Cambridge CB10 1XL, U.K.
出版信息
Sci Transl Med. 2016 Oct 26;8(362):362ps17. doi: 10.1126/scitranslmed.aaf9246.
Poly(ADP-ribose) polymerase (PARP) inhibitors are the first DNA damage response targeted agents approved for cancer therapy. Here, we focus on their molecular mechanism of action by PARP "trapping" and what this means for both clinical monotherapy and combination with chemotherapeutic agents.
聚（ADP-核糖）聚合酶（PARP）抑制剂是首批获批用于癌症治疗的 DNA 损伤反应靶向药物。在这里，我们重点讨论 PARP“捕获”的分子作用机制，以及这对临床单药治疗和与化疗药物联合治疗的意义。
Zotero 插件